Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)LeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Amphastar Pharmaceuticals (AMPH) Receivables - Net (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Receivables - Net data on record, last reported at $146.8 million in Q3 2025.

  • For Q3 2025, Receivables - Net rose 5.14% year-over-year to $146.8 million; the TTM value through Sep 2025 reached $146.8 million, up 5.14%, while the annual FY2024 figure was $136.3 million, 18.57% up from the prior year.
  • Receivables - Net reached $146.8 million in Q3 2025 per AMPH's latest filing, up from $133.0 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $146.8 million in Q3 2025 and bottomed at $67.9 million in Q2 2021.
  • Average Receivables - Net over 5 years is $106.9 million, with a median of $104.7 million recorded in 2023.
  • Peak YoY movement for Receivables - Net: fell 6.12% in 2022, then soared 54.33% in 2023.
  • A 5-year view of Receivables - Net shows it stood at $78.8 million in 2021, then grew by 12.69% to $88.8 million in 2022, then rose by 29.43% to $114.9 million in 2023, then rose by 18.57% to $136.3 million in 2024, then rose by 7.72% to $146.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Net were $146.8 million in Q3 2025, $133.0 million in Q2 2025, and $144.6 million in Q1 2025.